OncoResponse's Series A - II Round

OncoResponse raised a round of funding on May 26, 2016. Investors include Baxalta.

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded…

Articles about OncoResponse's Series A - II Round: